The long-term efficacy of adalimumab is well maintained in patients who experience an initial response of 75 percent or greater improvement in the Psoriasis Area and Severity Index score (PASI 75), according to a study published in the February issue of the Journal of the American Academy of Dermatology.
Kenneth Gordon, M.D., of the University of Chicago Pritzker School of Medicine, and colleagues analyzed data from an open-label extension to the REVEAL trial. Patients who received adalimumab continuously from baseline were grouped by their responses in the REVEAL trial. Results from patients who began adalimumab after 16 weeks of placebo therapy were also included in the analyses.
The researchers found that efficacy was generally well maintained over three years for patients with sustained PASI 75 responses during REVEAL, with 75/90/100 percent improvement in PASI score response rates (last observation carried forward) of 83/59/33 percent after 100 weeks and 76/50/31 percent after 160 weeks of continuous therapy. Long-term PASI 75 responses were seen for some patients with less than PASI 75 responses in REVEAL. In the placebo/adalimumab group, efficacy was consistent with the results from the other groups. The rates of adverse events were similar with those reported during REVEAL.
"Adalimumab efficacy was well maintained over more than three years of continuous therapy for patients with sustained initial PASI 75 responses," the authors write.
Several authors disclosed financial ties to pharmaceutical companies, including Abbott, which funded the study and manufactures adalimumab.
Copyright © 2012 HealthDay. All rights reserved.
For articles on psoriasis in the Cutis archive, go to our Topic Collection.